In addition, the breast pCR rate and the pCR rate were highest in patients with HER2+ breast cancer (66.3% and 62.8%), followed by TNBC (48.5% and 45.0%), and HR+HER2- breast cancer (8.9% and 4.3%). Here, ERBB2 is linked to breast carcinoma.